Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Rapid Finger-Prick test could help shield cancer patients from COVID-19

NCT ID NCT04492410

Diagnosis Sponsor: Centre Antoine Lacassagne Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study tested a quick finger-prick blood test to see if cancer patients had been infected with COVID-19 in the past. Researchers enrolled 214 adults being treated for cancer. The goal was to find out how many had antibodies, including those without symptoms, to help clinics keep infected and non-infected patients apart and plan safer cancer care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
rapid serological test (finger-prick blood test)
What this could lead to
If successful, this screening method could help cancer clinics quickly identify patients who have had COVID-19, allowing safer separation of infected and non-infected patients during treatment.
What could go wrong
This was a small, completed study focused on measuring infection rates, not on treating disease. The rapid test may be less accurate than standard lab tests, and results may not apply to all cancer patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

214 people

The number who actually took part.

Started

Jul 2020

Finished

Nov 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18-years old; 2. Patient treated for histologically proven cancer; 3. Patient that require at least one visit for anti-cancer treatment in a one-day outpatient care units 4. Patients that have previously been tested positive with a RT-PCR test from nasal swab that have been authorized to come to the hospital (after recovery or a 14-days quarantine period, according to local guidelines) can be included. 5. Patient willing and able to provide written informed consent/assent for the trial; 6\. Patient affiliated with a health insurance system. Exclusion Criteria: 1. Patient not able to give free consent 2. Patient not able to understand the protocol; 3. Patient not able to undergo the COVID-19 test 4. Vulnerable persons as defined by article L1121-5 - 8: 1. Pregnant women, women in labour or breast-feeding mothers, persons deprived of their freedom by judicial or administrative decision, persons hospitalized without their consent by virtue of articles L. 3212-1 and L. 3213-1 and who are not subject to the provisions of article L. 1121-8 2. Persons admitted to a social or health facility for reasons other than research 5. Adults subject to a legal protection order or unable to give their consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer COVID-19 neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer

Contacts and locations

Locations

  • Centre Antoine Lacassagne

    Nice, France, 06189, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.